ST. PAUL, Minn. , Oct.
8, 2024 /PRNewswire/ -- ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH ) and CellReadyTM, today announced that Eric Tran , Ph.D, Associate Member of the Earle A. Chiles Research Institute, a division of the Providence Cancer Institute, has been awarded a G-Rex Grant.
Dr. Tran's $200,000 G-Rex Grant will enable process development and IND enabling studies of a novel KRAS-targeted TCR-T cell therapy. "We have utilized G-Rex devices for a long time for our adoptive cell therapy efforts.
This G-Rex Grant will substantially defray the costs associated with bringing our next generation TCR-T cell therapy into the clinic and advance the state of our manufacturing," said Dr. Tran "Dr. Tran has been contributing to the field of cell and gene therapy for nearly 15 years and we are grateful for the opportunity to award a G-Rex Grant to Dr.
Tran and the Providence Cancer Institute. Providence's G-Rex Grant will help expedite an IND application of their novel KRAS-targeted TCR T-cell therapy to treat a variety of solid tumors in a Phase 1/ 1b clinical trial," said John Wilson , CEO of Wilson Wolf and co-inventor of G-Rex. As part of the G-Rex Grant, Dr.
Tran plans to optimize their manufacturing process by reducing the process duration and implementing fully-closed system G-Rex bioreactors. Dr. Tran will make use of Bio-Techne's new GMP cytokines that have been right-sized for one-touch G-Rex close process manufac.
